Grants for Independent school districts - Health

This funding opportunity supports research projects that explore innovative combinations of radiation therapy and other treatments to improve cancer care, inviting applications from a diverse range of organizations, including universities, nonprofits, and for-profit entities.

This funding opportunity supports small-scale research projects that aim to improve the use of genomic information in clinical care, particularly for diverse and historically underrepresented populations.

This Funding Opportunity Announcement (FOA) invites applications to develop and implement Phase Ib to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and other age-related dementias using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure.Research Objectives Utilizing the ACTC, the goal of this FOA is to invite research grant applications that provide clinical testing (Phases Ib-III) of promising pharmacological and/or non-pharmacological interventions for cognitive and neuropsychiatric symptoms in individuals with AD or other aging-related dementias across the spectrum from pre-symptomatic to more severe stages of disease. Working with the ACTC is a cooperative venture between the applicant, the NIA, and the ACTC network. NIA and the ACTC leadership will provide guidance to potential applicants. Potential applicants are strongly encouraged to contact NIA Scientific/Research Contacts (see Agency Contacts, Section VII) and the ACTC study team in order to discuss the feasibility of conducting the proposed trial through the ACTC infrastructure before considering an application. The ACTC infrastructure is welcoming of the following: Academic and industry applicants Pharmacological and non-pharmacological interventions Applications are encouraged that propose the following: Testing candidate therapeutic compounds against novel therapeutic targets Testing repurposed drugs derived from data-driven approaches, including candidates coming from NIA's translational bioinformatics FOA (PAR-17-032) Logistical guidance: Potential applicants undergo initial vetting of proposed study by the ACTC protocol evaluation committee and final review by the steering committee. Applicants should contact the ACTC study team at least 5 months prior to their desired NIA submission cycle. Contact details and more information may be found at actcinfo.org. Applications should anticipate using a centralized IRB. Applicants should be aware of the data and resource sharing requirements. The use of common contract language is strongly encouraged. Note, the ACTC infrastructure is not appropriate for: Single site clinical trials Routine Phase Ia first-in-human Clinical trials funded from this FOA will be implemented through the ACTC. The clinical trials approved for funding will develop their final protocols in conjunction with the ACTC. All ACTC sites will have the option to request participation and will be selected based on their capabilities specific to the individual protocols. Investigators are strongly encouraged to collect blood and other biosamples for future genomic and other 'omic' analyses aimed at interrogating treatment responsiveness and examining predictors of decline and progression. See Section VIII. Other Information for award authorities and regulations.

This funding opportunity provides financial support to a range of organizations working internationally to improve the detection, notification, and response to infectious disease outbreaks in partner countries, enhancing global health security.

This funding opportunity is designed to support higher education institutions, nonprofit organizations, and other eligible entities in establishing a coordination center to advance research on how our bodies sense and respond to internal signals, with a focus on improving mental health and overall wellness.

This funding opportunity supports research projects that improve the use of mammalian models, like organoids and tumoroids, to advance cancer research and develop effective treatments for patients.

This funding opportunity supports innovative research exploring how social isolation and loneliness contribute to suicide risk among older adults, particularly focusing on underrepresented communities and various social factors.

NIEHS invites applications for cooperative agreements to support the development of model programs for the training and education of workers engaged in activities related to hazardous materials and waste generation, removal, containment, transportation and emergency response within the Department of Energy (DOE) nuclear weapons complex. The aim of this funding opportunity is to prevent work-related harm through safety and health training. The training programs consist of information and practical exercises with the objective of raising the knowledge of workers in protecting themselves and the community from being exposed to hazardous materials encountered during hazardous waste operations; facility decommissioning and decontamination; hazardous materials transportation; environmental restoration of contaminated facilities; or chemical emergency response. Currently, tens of thousands of DOE employees are required to complete safety and health training. The goal of this training is to help reduce the risk of workers being exposed during work activities to hazardous materials and hazardous waste products. The NIEHS/DOE Nuclear Worker Training Program enhances training capabilities at these sites.

This funding opportunity supports organizations that provide comprehensive services for individuals facing substance use disorders, mental health issues, criminal justice involvement, and housing instability, helping them stabilize and reintegrate into society.

This funding opportunity provides financial and technical support to organizations working to improve HIV care and reduce transmission among low-income and vulnerable populations across the United States.

The National Center for Advancing Translational Sciences (NCATS) intends to publish aNotice of Funding Opportunity (NOFO) to solicit applications for research to advance the diagnosis, management, and treatment of rare diseases. Each Rare Diseases Clinical Research Consortium (RDCRC) will promote highly collaborative, multi-site, patient-centric, translational, and clinical research. It is strongly encouraged that the RDCRC study outcome measures include those that address unmet clinical trial readiness needs that will move the field of research forward from its current state. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in winter 2024, with an expected application due date in summer 2024. This NOFO will utilize the U54 activity code, which supports specialized centers through multi-project cooperative agreement awards to support research activities with substantial involvement from NIH program staff. Details of the planned NOFO are provided below.

This funding opportunity supports organizations in planning and hosting an annual conference focused on advancing the development of treatments for substance use disorders, bringing together researchers, clinicians, and policymakers to foster collaboration and innovation in this critical public health area.

This funding opportunity supports research projects that aim to reduce health disparities related to HIV and substance use among underserved racial and ethnic populations in the U.S.

This grant provides funding for researchers to develop small molecule drugs targeting nervous system disorders, with support from NIH resources for drug discovery and clinical testing.

The purpose of this concept is to facilitate the formation and maintenance of multidisciplinary research teams ready to employ epidemiological and/or etiological datasets and analyses to answer substance use prevention research questions and apply findings to intervention development or implementation. Projects supported through this concept will combine hands-on meeting formats, including both sandpit and hackathon approaches, with activities to sustain new research teams and networks, creating a foundational structure for research programs that have impact across disciplines.

This funding opportunity provides financial support to a range of organizations working in Kenya to strengthen health systems for effective management and control of HIV and TB, while promoting sustainable healthcare practices and improving public health responses.

This funding opportunity provides financial support to organizations that create programs helping low-income pregnant and postpartum women access fresh fruits and vegetables, along with nutrition education, to improve their health and that of their families.

This funding opportunity supports interdisciplinary research centers focused on advancing the understanding and treatment of communication disorders, such as hearing and speech issues, through collaborative projects and clinical trials.

This funding opportunity supports advanced pre-clinical research projects that utilize nanotechnology to improve cancer treatment and diagnostics, aiming to transition these innovations toward clinical applications.

This funding opportunity supports early-career researchers in the U.S. to develop their skills in implementation science for effective substance use prevention and treatment, enabling them to lead clinical trials that address the opioid crisis.